ArticleRenal failure2025
Transition to a combination of peritoneal dialysis and hemodialysis in chronic kidney disease patients receiving peritoneal dialysis treatment: a single-center study.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Understanding Patients' Experiences and Adherence Challenges with Dietary and Fluid Restriction in End-Stage Kidney Disease: A Qualitative Study.Patient preference and adherence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal dialysis (PD) and hemodialysis (HD) are the two primary renal replacement therapies for patients with end-stage renal disease (ESRD). While PD is an effective and convenient modality, long-term use can lead to ultrafiltration failure, recurrent peritonitis, and progressive structural alterations in the peritoneal membrane, necessitating a transition to HD. In recent years, rather than a complete transition, the combined use of PD and HD has emerged as a viable alternative, offering potential advantages for selected patient populations.This retrospective study included patients with PD-related complications, such as resistant hypervolemia, frequent peritonitis episodes, peritoneal failure, and clinical deterioration. Based on eligibility criteria, patients were either transitioned to HD or initiated on combined PD+HD therapy. A total of 28 patients underwent transition to HD, while 26 received PD+HD combination therapy. Survival rates, Kt/V, residual urine output, and various laboratory parameters were evaluated and compared between the two groups. Both groups demonstrated significant improvements in Kt/V, volume stabilization, and cardiovascular stability after transitioning from PD. However, no statistically significant differences were observed in laboratory parameters between the two groups. These findings suggest that for patients experiencing PD failure, frequent peritonitis, or fluid overload, combined PD+HD therapy may serve as a feasible alternative to conventional HD. Careful patient selection and individualized treatment planning are crucial for optimizing outcomes. Given its comparable efficacy to HD, combined PD+HD therapy may represent an important option for patients requiring a tailored approach to dialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.